CompletedPhase 2ACTRN12606000031561

C FEN 0205

a randomised, double-blind, placebo-controlled study assessing the effect of fenofibrate, coenzyme Q10 and their co-administration on ventricular disatolic function in patients with type 2 diabetes

Sponsor

Fournier Laboratory Ireland

Enrollment

125 participants

Start Date

Jun 1, 2003

Study Type

Interventional

Conditions

Type 2 diabetes with left ventricular diastolic dysfunction (LVDD)

Eligibility

Sex: Both males and femalesMin Age: 40 YearssMax Age: 79 Yearss

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying C FEN 0205. You may be eligible if you are people aged 40 to 79 with type 2 diabetes patients with lvdd and lv ejection fraction equal or greater than 50%. Participation typically involves medical assessments, possible treatment with the study intervention, and follow-up visits to track your health.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

fenofibrate 80mg + CoEnz Q10 100mg fenofibrate 80mg + CoEnz Q10 200mg fenofibrate 160mg + CoEnz Q10 100mg fenofibrate 160mg + CoEnz Q10 200mg fenofibrate 160mg CoEnz Q10 200mg 6 MONTHS INTERVE

fenofibrate 80mg + CoEnz Q10 100mg fenofibrate 80mg + CoEnz Q10 200mg fenofibrate 160mg + CoEnz Q10 100mg fenofibrate 160mg + CoEnz Q10 200mg fenofibrate 160mg CoEnz Q10 200mg 6 MONTHS INTERVENTION

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12606000031561